Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses
Removes PD-1 Inhibitor, Adds To Radioligand Pipeline
The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.
